Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

[1]  M. Maurer,et al.  Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis , 2019, Journal of clinical neuromuscular disease.

[2]  S. Solomon,et al.  Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study , 2019, Circulation.

[3]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[4]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[5]  S. Solomon,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[6]  K. G. Rajeev,et al.  Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity , 2018, Nature Communications.

[7]  S. Milstein,et al.  Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  Lawrence A Leiter,et al.  Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol , 2017, The New England journal of medicine.

[9]  B. Bettencourt,et al.  A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 , 2017, The New England journal of medicine.

[10]  B. Bettencourt,et al.  Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  A. Dispenzieri,et al.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. , 2016, Journal of the American College of Cardiology.

[12]  P. Hawkins,et al.  Evolving landscape in the management of transthyretin amyloidosis , 2015, Annals of medicine.

[13]  B. Bettencourt,et al.  Rapid progression of familial amyloidotic polyneuropathy , 2015, Neurology.

[14]  A. Dispenzieri,et al.  Hereditary ATTR amyloidosis: a single-institution experience with 266 patients , 2015, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[15]  D. Judge,et al.  Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis , 2015, Journal of Cardiovascular Translational Research.

[16]  D. Judge,et al.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs , 2015, Heart Failure Reviews.

[17]  P. Hawkins,et al.  Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations , 2014, Human mutation.

[18]  M. Hanna.  Novel Drugs Targeting Transthyretin Amyloidosis , 2014, Current Heart Failure Reports.

[19]  P. Cosnay,et al.  Cardiac amyloidosis: updates in diagnosis and management. , 2013, Archives of cardiovascular diseases.

[20]  F. Salvi,et al.  Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. , 2013, European heart journal.

[21]  M. Maurer,et al.  THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis , 2013, Current medical research and opinion.

[22]  J. Berk,et al.  Transthyretin (TTR) Cardiac Amyloidosis , 2012, Circulation.

[23]  L. Anderson,et al.  Cardiac transthyretin amyloidosis , 2012, Heart.

[24]  R. Falk,et al.  Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). , 2012, American heart journal.

[25]  P. Hawkins,et al.  Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. , 2012, European heart journal.

[26]  K. Dharmarajan,et al.  Transthyretin Cardiac Amyloidoses in Older North Americans , 2012, Journal of the American Geriatrics Society.

[27]  S. Thibodeau,et al.  Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period. , 1992, Mayo Clinic proceedings.

[28]  E. Schon,et al.  Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. , 1985, The Journal of biological chemistry.